Add time:07/16/2019         Source:sciencedirect.com

BackgroundPreterm birth is the leading cause of neonatal morbidity and mortality in nonanomalous neonates in the United States. Women with a previous early spontaneous preterm birth are at highest risk for recurrence. Weekly intramuscular 17-alpha hydroxyprogesterone caproate reduces the risk of recurrent prematurity. Although current guidelines recommend 17-alpha hydroxyprogesterone caproate initiation between 16 and 20 weeks, in clinical practice, 17-alpha hydroxyprogesterone caproate is started across a spectrum of gestational ages.

We also recommend Trading Suppliers and Manufacturers of 14-Hydroxyprogesterone (cas 16031-66-6). Pls Click Website Link as below: cas 16031-66-6 suppliers